Previous 10 | Next 10 |
home / stock / gnmsf / gnmsf news
The FDA approves Johnson & Johnson ( JNJ -0.5% ) unit Janssen Biotech's Darzalex (daratumumab), combined with Celgene's Revlimid (lenalidomide) and dexamethasone, for the first-line treatment of multiple myeloma (MM) patients who are ineligible for autologous stem cell transplantatio...
BlackRock ( BLK -1.1% ) has decreased its stake in Genmab A/S ( OTCPK:GNMSF +0.5% ) to less than 5%. More news on: BlackRock, Inc., Genmab A/S, Financial stocks news, Healthcare stocks news, Read more ...
Genmab A/S (GNMSF) Q1 2019 Earnings Conference Call May 8, 2019, 12:00 PM ET Company Participants Jan van de Winkel - Co-Founder, CEO and President David Eatwell - EVP and CFO Conference Call Participants Wimal Kapadia - Sanford C. Bernstein & Co. Thomas Bowers - Danske...
The following slide deck was published by Genmab A/S in conjunction with their 2019 Q1 earnings Read more ...
Genmab A/S ( OTCPK:GNMSF ) announces that Janssen Pharmaceutica NV has submitted a Type II variation application to the EMA. More news on: Genmab A/S, Genmab A/S, Healthcare stocks news, Read more ...
The following slide deck was published by Genmab A/S in conjunction with this Read more ...
Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage. Genmab ( GNMSF ) and their par...
Genmab A/S ( OTCPK:GNMSF ) announces that a Phase 3 clinical trial, MAIA , evaluating licensee Janssen Biotech's (NYSE: JNJ ) DARZALEX (daratumumab), combined with Celgene's (NASDAQ: CELG ) REVLIMID (lenalidomide) and dexamethasone (DRd), compared to REVLIMID and dexamethasone alone (Rd) ...
Noteworthy events during the week of October 14 - 20 for healthcare investors. More news on: Cannabics Pharmaceuticals Inc., Soligenix, Inc., Aeglea BioTherapeutics, Healthcare stocks news, , Read more ...
Fresenius Medical Care ( FMS +1.5% )( OTCPK:FMCQF )( OTCPK:FSMEM ) assumed with Hold rating and €82 price target at Jefferies. More news on: Fresenius Medical Care AG & Co. KGAA, Fresenius Medical Care AG & Co KGaA, Fresenius Medical Care Holdings, Healthcare stocks news, ...
News, Short Squeeze, Breakout and More Instantly...
Company Announcement Positive CHMP opinion based on results from the Phase 1/2 EPCORE ® NHL-1 study FL is the second most common type of NHL and accounts for approximately 20-30 percent of all global cases If approved, epcoritamab (TEPKINLY ® ...
Company Announcement Genmab has completed acquisition of ProfoundBio for USD 1.8 billion in cash Acquisition gives Genmab worldwide rights to three candidates in clinical development, including rinatabart sesutecan (Rina-S), plus ProfoundBio’s novel antibody-drug conjugat...
May 2, 2024 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2024 Highlights The U.S. Food and Drug Administration (U.S. FDA) granted Priority Review for the supplemental Biologics License Application (sBLA) for EPKINLY ® (epcorita...